Skip to main content
SpringerLink
Log in

Tumour necrosis factor-α blockers: increasing the options for managing rheumatoid arthritis

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Keating GM, Jarvis B. Management of rheumatoid arthritis: defining the role of etanercept. Dis Manage Health Outcomes 2002; 10(1): 17–39

    Article  CAS  Google Scholar 

  2. Jarvis B, Faulds D. Etanercept. A review of its use in rheumatoid arthritis. Drugs 1999 Jun; 57(6): 945–66

    Article  PubMed  CAS  Google Scholar 

  3. Wolfe F, Cush JJ, O’Dell JR, et al. Consensus recommendations for the assessment and treatment of rheumatoid arthritis. J Rheumatol 2001 Jun; 28: 1423–30

    PubMed  CAS  Google Scholar 

  4. Markham A, Lamb HM. Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs 2000 Jun; 59(6): 1341–59

    Article  PubMed  CAS  Google Scholar 

  5. Richard-Miceli C, Dougados M. Tumour necrosis factorα blockers in rheumatoid arthritis. BioDrugs 2001; 15(4): 251–59

    Article  PubMed  CAS  Google Scholar 

  6. British National Formulary. No 42. London: The Pharmaceutical Press, 2001 Sep: 485

  7. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor amonoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999; 354: 1932–9

    Article  PubMed  CAS  Google Scholar 

  8. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586–93

    Article  PubMed  CAS  Google Scholar 

  9. Spencer-Green G, Genovese M, Martin RW, et al. Etanercept versus methotrexate in early rheumatoid arthritis (ERA trial): two-year follow-up [abstract]. J Rheumatol 2001 Jul; 28 Suppl. 63: 106

    Google Scholar 

  10. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis: a randomized controlled study. Arch Intern Med 1999; 130: 478–86

    CAS  Google Scholar 

  11. Weinblatt ME, Kremer JM, Bankhurst, AD, et al. A trial of etanercept, a recombinant tumour necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999; 340: 253–9

    Article  PubMed  CAS  Google Scholar 

  12. Jones M, Symmons D, Finn J, et al. Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study. Br J Rheumatol 1996; 35: 738–45

    Article  PubMed  CAS  Google Scholar 

  13. Infliximab (Remicade®): prescribing information. Malvern (PA): Centocor, 1999.

  14. Smolen JS, Steiner G, Breedveld FC, et al. Anti-TNFα therapy and drug-induced lupus-like syndrome [abstract no. 906]. Ann Rheum Dis 1999 Jun 6; EULAR Suppl.: 217

    Google Scholar 

  15. Emery P, Reginster JY, Appelboom T, et al. WHO Collaborating Centre consensus meeting on anti-cytokine therapy in rheumatoid arthritis. Rheumatology (Oxford) 2001; 40: 699–702

    Article  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tumour necrosis factor-α blockers: increasing the options for managing rheumatoid arthritis. Drugs Ther. Perspect 18, 16–20 (2002). https://doi.org/10.2165/00042310-200218050-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200218050-00006

Keywords

Search

Navigation